Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.36 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | HPGDS | O60760 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10034786 | 0.80 | SSTR3 (0.36) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL9977148 | 0.78 | RPS6KB1 (0.41) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL881321 | 0.77 | PRCP (0.47) | KCNH2HPGDS | |
| SCHEMBL16577384 | 0.76 | RPS6KB1 (0.46) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL9977153 | 0.76 | SCN10A (0.42) | KCNH2SCN10AHPGDS | |
| SCHEMBL9977152 | 0.75 | RPS6KB1 (0.39) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL10034783 | 0.73 | HPGDS (0.47) | KCNH2HPGDS | |
| SCHEMBL9977151 | 0.73 | RPS6KB1 (0.39) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL16352857 | 0.72 | HPGDS (0.46) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 | |
| SCHEMBL9977195 | 0.72 | MAPK13 (0.52) | SSTR3SSTR5KCNH2SCN10ARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | SLC6A4 4107/4885SSTR3 4426/4885SSTR5 4662/4885 |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | SLC6A4 4107/4885SSTR3 4426/4885SSTR5 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.